PRESS RELEASE PR Newswire
Apr. 13, 2022, 06:00 AM
Nuvaxovid™ is the first protein-based COVID-19 vaccine authorized for use in Switzerland
GAITHERSBURG, Md., April 13, 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing...
adar poonawalla chief executive officer serum institute
country: unknown
earth messiah amen gaithersburg md
existing vaccine supply chain
matrix m adjuvant
next generation vaccines
novavax' recombinant nanoparticle protein
serious infectious diseases
stanleycerckpresident
united kingdom australia
50 microgram matrix m adjuvant
chief executive officer novavax
chief executive officer sk bioscience
coronavirus spike s protein
country: unknown
novavax' recombinant nanoparticle technology
protein based vaccine candidate
saponin based matrix m adjuvant
stanleycerckpresident
two pivotal phase 3 trials